Andrew B Adams
Overview
Explore the profile of Andrew B Adams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adams A, Faber D, Lovasik B, Matar A, Kim S, Burlak C, et al.
Xenotransplantation
. 2024 Aug;
31(4):e12880.
PMID: 39185772
Objective: To evaluate the clinically relevant anti-CD40 antibody iscalimab for baseline immunosuppression in a preclinical pig-to-rhesus renal xenograft model. Summary Background Data: CD40/CD40L co-stimulation blockade-based immunosuppression has been more successful...
2.
Leishman D, Oppler S, Stone L, OBrien T, Ramachandran S, Willenberg B, et al.
Front Transplant
. 2024 Jul;
3():1352777.
PMID: 38993753
Introduction: Successful diabetes reversal using pancreatic islet transplantation by various groups illustrates the significant achievements made in cell-based diabetes therapy. While clinically, intraportal islet delivery is almost exclusively used, it...
3.
Vock D, Humphreville V, Ramanathan K, Adams A, Lim N, Nguyen V, et al.
Liver Transpl
. 2024 May;
31(1):32-44.
PMID: 38727598
Indications for liver transplants have expanded to include patients with alcohol-associated liver disease (ALD) over the last decade. Concurrently, the liver allocation policy was updated in February 2020 replacing the...
4.
Khush K, Bernat J, Pierson 3rd R, Silverman H, Parent B, Glazier A, et al.
Am J Transplant
. 2024 Mar;
24(6):918-927.
PMID: 38514013
Xenotransplantation offers the potential to meet the critical need for heart and lung transplantation presently constrained by the current human donor organ supply. Much was learned over the past decades...
5.
Adams A, Blumberg E, Gill J, Katz E, Kawai T, Schold J, et al.
Am J Kidney Dis
. 2024 Mar;
84(1):94-101.
PMID: 38452918
Chronic kidney disease affects an estimated 37 million people in the United States; of these,>800,000 have end-stage renal disease requiring chronic dialysis or a kidney transplant to survive. Despite efforts...
6.
Lovasik B, Kim S, Higginbotham L, Wakwe W, Mathews D, Breeden C, et al.
bioRxiv
. 2023 May;
PMID: 37205571
Costimulation blockade using belatacept results in improved renal function after kidney transplant as well as decreased likelihood of death/graft loss and reduced cardiovascular risk; however, higher rates and grades of...
7.
Tector A, Adams A, Tector M
Kidney360
. 2023 Feb;
4(2):278-284.
PMID: 36821619
Renal transplantation is the preferred treatment of ESKD, but the shortage of suitable donor kidneys from the cadaver pool means that many patients with ESKD will not receive a kidney...
8.
Badell I, Bray R, Elbein R, Chami A, Easley K, Pastan S, et al.
Transplantation
. 2021 Nov;
105(12):e395-e396.
PMID: 34818307
No abstract available.
9.
Adams A, Lovasik B, Faber D, Burlak C, Breeden C, Estrada J, et al.
Ann Surg
. 2021 Jul;
274(3):473-480.
PMID: 34238812
Objective: Pig-to-primate renal xenotransplantation is plagued by early antibody-mediated graft loss which precludes clinical application of renal xenotransplantation. We evaluated whether temporary complement inhibition with anti-C5 antibody Tesidolumab could minimize...
10.
Kirk A, Adams A, Durrbach A, Ford M, Hildeman D, Larsen C, et al.
Am J Transplant
. 2020 Oct;
21(5):1691-1698.
PMID: 33128812
Kidney transplant recipients administered belatacept-based maintenance immunosuppression present with a more favorable metabolic profile, reduced incidence of de novo donor-specific antibodies (DSAs), and improved renal function and long-term patient/graft survival...